MyFinsight
Home
Blog
About
Contact
Download
Download image
Revenues
$874,837K
(94.10%↑ Y/Y)
Other income
$12,090K
Interest income
$10,668K
(-27.65%↓ Y/Y)
Net income (loss)
$263,861K
(396.87%↑ Y/Y)
Stock-based compensation
expense
$85,066K
(30.04%↑ Y/Y)
Canceled cashflow
$633,734K
Increase in accounts
payable and accrued...
$57,802K
(192.66%↑ Y/Y)
Non-cash interest
expense on royalty...
$53,163K
Equity modification
associated with sale of...
$17,548K
Loss on
extinguishment of debt
-$17,332K
Depreciation and
amortization
$1,389K
(11.48%↑ Y/Y)
Non-cash interest
expense on secured term...
$1,387K
(-97.95%↓ Y/Y)
Inventory obsolescence
$985K
(-27.04%↓ Y/Y)
Net cash provided by
(used in) operating...
$347,369K
(767.76%↑ Y/Y)
Effect of exchange
rates on cash, cash...
$1,270K
(235.68%↑ Y/Y)
Canceled cashflow
$151,164K
Sales and marketing
(excluding stock-based...
$177,085K
General and
administrative (excluding...
$116,006K
Stock-based compensation
$85,066K
Interest expense
$78,872K
(-19.94%↓ Y/Y)
Research and development
(excluding stock-based...
$51,576K
Research and development
(excluding stock-based...
$27,958K
Cost of product sales
$19,075K
(55.47%↑ Y/Y)
Research and development
(excluding stock-based...
$17,677K
Loss on
extinguishment of debt
-$17,332K
Research and development
(excluding stock-based...
$17,304K
(-46.62%↓ Y/Y)
Research and development
(excluding stock-based...
$12,148K
(-73.02%↓ Y/Y)
Research and development
(excluding stock-based...
$9,497K
Income tax expense
$3,530K
(83.19%↑ Y/Y)
Research and development
(excluding stock-based...
$456K
(-98.11%↓ Y/Y)
Foreign currency
losses, net
-$152K
Decrease in cash, cash
equivalents and restricted...
-$14,986K
(-144.71%↓ Y/Y)
Canceled cashflow
$348,639K
Net proceeds from
common stock issued...
$9,115K
(164.66%↑ Y/Y)
Common stock issued to
directors in lieu of cash...
$59K
(73.53%↑ Y/Y)
Sales and maturities
of investments
$256,647K
(-19.92%↓ Y/Y)
Sale of
non-financial asset
$550K
Decrease in royalty
financing obligations
$68,428K
Increase in receivables
$36,806K
(62.16%↑ Y/Y)
Payment of pharmakon pik
interest
$23,704K
(increase) decrease in
prepaid expenses and...
$7,827K
(499.54%↑ Y/Y)
Amortization of discount on
investments, net
-$4,331K
(62.25%↑ Y/Y)
Mark-to-market adjustment on
share-based liability
$4,313K
Gain on sale of
biocryst ireland
$3,566K
Increase in inventory
$1,639K
(-60.64%↓ Y/Y)
Gain on sale of
non-financial asset
$550K
Net cash (used in)
provided by financing...
-$349,931K
(-5974.14%↓ Y/Y)
Canceled cashflow
$9,174K
Net cash (used in)
provided by investing...
-$13,694K
(-126.04%↓ Y/Y)
Canceled cashflow
$257,197K
Repayment of principal on
term loans
$300,000K
Principal payments on
royalty financing...
$22,883K
Payment of royalty
release fees
$15,500K
Prepayment premium and fees
on term loans
$9,886K
Withholding taxes paid on
stock-based awards
$8,847K
(17.41%↑ Y/Y)
Principal payments on
finance lease...
$1,989K
(16.73%↑ Y/Y)
Purchases of investments
$262,240K
(-1.70%↓ Y/Y)
Proceeds from sale of
biocryst ireland, net of...
-$6,183K
Acquisitions of property and
equipment
$2,468K
(119.57%↑ Y/Y)
Back
Back
Cash Flow
source: myfinsight.com
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)